Cancer · Austria
Acute myeloid leukaemia
How is it diagnosed today? Your family doctor usually arranges an urgent blood test, and may send you to a hospital specialist or straight to hospital. NHS
What do you need help with?
- Join a trialStudies open to new patients in your country, and abroad if you want.13 open trials in Austria
- Offer tissue or dataGive a sample or your health data to research.
- Get supportPatient groups, money and work, help for family.
- Access and costGetting a treatment that is not on offer here, and who pays.
- Questions for your doctorReady lists to print or copy before your next visit.
- Don't pay for thisOffers with no proof in people, and what to check first.
Where treatment stands
Four steps, from proven to unproven.
Approved in Austria
Usual treatment: Intensive chemo, sometimes a stem cell transplant. NHS
15 medicines are approved for this disease in Austria:
Show all 15
- Arsenic trioxide (Trisenox, Arsenic trioxide Accord, Arsenic trioxide medac) – approved in 2002
- Azacitidine (Onureg, Azacitidine Mylan, Azacitidine Kabi) – approved in 2008
- Cedazuridine and decitabine (Inaqovi, Inqovi) – approved in 2023
- Daunorubicin and cytarabine (Vyxeos liposomal, Vyxeos) – approved in 2018
- Decitabine (Dacogen, Decitabin Sandoz) – approved in 2012
- Gemtuzumab ozogamicin (Mylotarg) – approved in 2018
- Gilteritinib (Xospata) – approved in 2019
- Glasdegib (Daurismo) – approved in 2020
- Histamine dihydrochloride (Ceplene) – approved in 2008
- Ivosidenib (Tibsovo) – approved in 2023
- Melphalan (Phelinun) – approved in 2020
- Midostaurin (Rydapt) – approved in 2017
- Quizartinib (Vanflyta) – approved in 2023
- Venetoclax (Venclyxto, Venclexta) – approved in 2016
- Posaconazole (Noxafil, Posaconazole Accord, Posaconazole AHCL) – approved in 2005
An EU approval is valid in Austria. We did not check the national approvals in Austria, so some medicines under “Approved elsewhere” may be approved here too. We did not check whether they are sold or paid for there. Checked in the regulators' own texts on 11 Nov 2026.
Approved elsewhere (17)
- Cyclophosphamide (Frindovyx) – approved for it in the US
- Cytarabine (Cytarabine, Aracytine, Cytarabine Sandoz) – approved for it in the US and France
- Daunorubicin (Daunorubicin Hydrochloride, Daunoblastin, Cerubidine) – approved for it in the US, Switzerland, and France
- Doxorubicin (Doxorubicin Hydrochloride) – approved for it in the US
- Enasidenib (Idhifa) – approved for it in the US
- Etoposide (Celltop, Etopophos) – approved for it in France
- Filgrastim (Neupogen) – approved for it in the US
- Idarubicin (Zavedos, Idamycin PFS, Idarubicine Accord) – approved for it in the US and France
- Mercaptopurine (Purinethol) – approved for it in France
- Mitoxantrone (mitoXANTRONE) – approved for it in the US
- Olutasidenib (Rezlidhia) – approved for it in the US
- Revumenib (Revuforj) – approved for it in the US
- Sargramostim (Leukine) – approved for it in the US
- Thioguanine (Tabloid, Lanvis) – approved for it in the US and France
- Treosulfan (Grafapex) – approved for it in the US
- Tretinoin (Tretinoin, Vesanoid) – approved for it in the US, Switzerland, and France
- Ziftomenib (Komzifti) – approved for it in the US
Being tested in people
13 open trials in Austria, 635 worldwide. See the trials
- 4 chemotherapy blocks: Course 1 AIE (cytarabine/idarubicin/etoposide), Course 2 AI (cytarabine/idarubicin), Course 3 HAD (high-dose cytarabine (1g)/daunorubicin), Course 4 HA (high-dose cytarabine). (Phase 3)
- AG-120 (Phase 3)
- AG-221 (Phase 3)
- all-trans retinoic acid (ATRA) (Phase 3)
Only in the lab or in animals
Of the 20 newest articles, 2 were in animals and 1 in the lab. See them
No proof it works
Animal worm medicines (ivermectin, fenbendazole) for cancer: not approved, and not enough research in people to know if they help. American Cancer Society: What to Know About Ivermectin (21 May 2026) · American Cancer Society: What to Know About Fenbendazole (21 Oct 2025)
Join a trial
Studies that are taking new patients in Austria. The trial team decides who can join. Change the country at the top.
Phase 1: first tests in people · Phase 2: does it help? · Phase 3: compared with the usual treatment
0 open trials in Austria with these filters
We found no open trial in Austria with these filters.
Available abroad (60 trials)
Nearest region first. Travel and treatment abroad are often not paid for; ask your health insurer first.
Long-term follow-up of people treated with AvenCell CAR-T cells in earlier trials
NCT07474051 · ClinicalTrials.gov
Countries: Germany
- Berlin, Germany – Charite Universitaetsmedizin Berlin KöR
- Dresden, Germany – Technische Universitaet Dresden
- Marburg, Germany – Philipps-Universitaet Marburg
Age 18 and over
Contact the trial teamTests CD19 CAR-T cells in adults with relapsed leukemia that expresses CD19
NCT06649227 · ClinicalTrials.gov
Countries: France
- Lille, France – CHU de Lille
Age 18 and over
Contact the trial teamCAR T cell treatment targeting CD70 in leukemia that has returned or persisted
NCT06345027 · ClinicalTrials.gov
Countries: United States
- Houston, United States – The Methodist Hospital
- Houston, United States – Texas Children's Hospital
Up to age 75
Contact the trial teamTests modified immune T cells against CD33 in adults with acute myeloid leukemia
NCT05672147 · ClinicalTrials.gov
Countries: United States
- Duarte, United States – City of Hope Medical Center
Age 18 and over
Contact the trial teamTests multi-target CAR T cell therapy in acute myeloid leukemia
NCT03222674 · ClinicalTrials.gov
Countries: China
- Shenzhen, China – Shenzhen Geno-immune Medical Institute
Ages 2 to 75
Contact the trial teamCAR T Cell Therapy Targeting CD7 in Blood Cancers
NCT04033302 · ClinicalTrials.gov
Countries: China
- Shenzhen, China – Shenzhen Geno-immune Medical Institute
Ages 0 to 75
Contact the trial teamTests universal CAR-T cells in people with relapsed or hard-to-treat acute myeloid leukemia
NCT05995041 · ClinicalTrials.gov
Countries: China
- Shenzhen, China – Shenzhen Geno-immune Medical Institute
Ages 0 to 75
Contact the trial teamCLEC2A CAR T cells for acute myeloid leukemia that returned or did not respond
NCT07905027 · ClinicalTrials.gov
Countries: United States
- Seattle, United States – Seattle Children's Hospital
Up to age 70
Contact the trial teamLong-term follow-up of people treated with ARD103 CAR-T cell therapy
NCT06906380 · ClinicalTrials.gov
Countries: United States
- Charlotte, United States – Novant Health Cancer Institute
- Houston, United States – MD Anderson Cancer Center
- Winston-Salem, United States – Novant Health Cancer Institute
No age limit given in the registry
Contact the trial teamTests CD83 CAR T cells in adults with relapsed or refractory acute myeloid leukemia
NCT06871410 · ClinicalTrials.gov
Countries: United States
- Buffalo, United States – Roswell Park Cancer Institute
Age 18 and over
Contact the trial teamCLL-1/CD70 CAR-T cell therapy for relapsed or hard-to-treat acute myeloid leukemia
NCT07897136 · ClinicalTrials.gov
Countries: China
- Beijing, China – Chinese PLA General Hospital
Age 18 and over
Contact the trial teamCD64 CAR T cells for adults with relapsed or refractory acute myeloid leukemia
NCT07347418 · ClinicalTrials.gov
Countries: United States
- Aurora, United States – University of Colorado Hospital
Age 18 and over
Contact the trial teamTests CD371 CAR T cells in people with relapsed acute myeloid leukemia
NCT06017258 · ClinicalTrials.gov
Countries: United States
- Basking Ridge, United States – Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
- Commack, United States – Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited Protocol Activities)
- Harrison, United States – Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Age 1 and over
Contact the trial teamSL1CC, an in-body CAR-T therapy, for acute myeloid leukemia that returned or resisted treatment
NCT07841002 · ClinicalTrials.gov
Countries: China
- Beijing, China – Chinese PLA General Hospital, Beijing, Beijing 100853
Ages 18 to 75
Contact the trial teamTests anti-FLT3 CAR-T cells in relapsed or refractory acute myeloid leukemia
NCT06786533 · ClinicalTrials.gov
Countries: United States
- Houston, United States – MD Anderson
Age 12 and over
Contact the trial teamTests CD123-targeted CAR-NK cells in relapsed or refractory leukemia or BPDCN
NCT06690827 · ClinicalTrials.gov
Countries: China
- Wuhan, China – Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Ages 18 to 75
Contact the trial teamTests modified immune T cells in children with relapsed or refractory acute myeloid leukemia
NCT06609928 · ClinicalTrials.gov
Countries: United States
- Seattle, United States – Fred Hutch/University of Washington/Seattle Children's Cancer Consortium
Up to age 6
Contact the trial teamFirst test of VTRU200, an immunotherapy, in relapsed blood cancers and solid tumors
NCT07749976 · ClinicalTrials.gov
Age 0 and over
Contact the trial teamTests modified stem cell transplant with CAR T cells for relapsed leukemia
NCT05945849 · ClinicalTrials.gov
Countries: United States
- Philadelphia, United States – University of Pennsylvania
Age 18 and over
Contact the trial teamTests CAR-T cells targeting CD33 and CLL1 in relapsed acute myeloid leukemia
NCT07668557 · ClinicalTrials.gov
Countries: China
- Nanchang, China – The First Affiliated Hospital of Nanchang University (Lead Site)
- Nanchang, China – Jiangxi Provincial People's Hospital (Participating Site)
Ages 18 to 70
Contact the trial teamTests CT0890B cell therapy in adults with relapsed or refractory acute myeloid leukemia
NCT07617285 · ClinicalTrials.gov
Countries: China
- Beijing, China – Peking University People's Hospital
Ages 18 to 70
Contact the trial teamFL-33 CAR T cells for hard-to-treat or returning acute myeloid leukaemia
NCT06326021 · ClinicalTrials.gov
Countries: China
- Beijing, China – BeijingGoBroadH
- Chengdu, China – The General Hospital of Western Theater Command PLA
- Shanghai, China – Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai
Ages 1 to 70
Contact the trial teamCAR T-cell therapy tested in young patients with CD123-positive blood cancers
NCT04318678 · ClinicalTrials.gov
Countries: United States
- Memphis, United States – St. Jude Children's Research Hospital
Up to age 21
Contact the trial teamCD19-CAR.p40-T cells for relapsed or treatment-resistant B cell blood cancers
NCT07584889 · ClinicalTrials.gov
Countries: China
- Shenzhen, China – Shenzhen university General Hospital
Ages 18 to 75
Contact the trial teamTests CD70 CAR-NK cell therapy in adults with returned T-cell lymphoma or leukemia
NCT06696846 · ClinicalTrials.gov
Countries: China
- Hangzhou, China – The Second Affiliated Hospital Zhejiang University School of Medicine
Ages 18 to 75
Contact the trial teamModified CD33 CAR-T cells for acute myeloid leukemia that returned or did not respond
NCT07538713 · ClinicalTrials.gov
Ages 14 to 75
Contact the trial teamDual-Target CAR-T Cell Therapy for Adults With Relapsed or Hard-to-Treat Blood Cancers
NCT07523555 · ClinicalTrials.gov
Countries: China
- Shenzhen, China – Peking University Shenzhen Hospital
Ages 18 to 75
Contact the trial teamADCLEC.syn1 CAR T cells for acute myeloid leukemia that returned or resisted treatment
NCT05748197 · ClinicalTrials.gov
Countries: United States
- Basking Ridge, United States – Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
- Commack, United States – Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities)
- Harrison, United States – Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Age 18 and over
Contact the trial teamTests CT1390B cell therapy in adults with relapsed or refractory acute myeloid leukemia
NCT07441980 · ClinicalTrials.gov
Countries: China
- Tianjin, China – Institute of Hematology & Blood Diseases Hospital, China
Ages 18 to 70
Contact the trial teamTests modified immune cells targeting CLL1 in relapsed or refractory acute myeloid leukemia
NCT07432100 · ClinicalTrials.gov
Ages 18 to 70
Contact the trial teamTests donor-derived CAR-NK cells chosen by tumor profile in advanced solid cancers
NCT07410494 · ClinicalTrials.gov
Countries: China
- Beijing, China – District One Hospital
Ages 8 to 85
Contact the trial teamCAR-T cell therapy for acute myeloid leukemia that returned or resisted treatment
NCT07370064 · ClinicalTrials.gov
Countries: China
- Xuzhou, China – The Affiliated Hospital oh Xuzhou Medical University
Ages 18 to 70
Contact the trial teamCD70 CAR T-cell therapy for children with hard-to-treat blood cancers
NCT06326463 · ClinicalTrials.gov
Countries: United States
- Memphis, United States – St. Jude Children's Research Hospital
Up to age 21
Contact the trial teamTests CLL1 CAR-T cells followed by stem cell transplant for relapsed acute myeloid leukemia
NCT07342244 · ClinicalTrials.gov
Countries: China
- Wuhan, China – Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Ages 18 to 78
Contact the trial teamTests SC-DARIC33 cell therapy in young people with relapsed CD33-positive leukemia
NCT05105152 · ClinicalTrials.gov
Countries: United States
- Seattle, United States – Seattle Children's Hospital
Up to age 30
Contact the trial teamCD7-targeted CAR-T cell therapy for relapsed or refractory T-cell leukemia or lymphoma and AML
NCT07153068 · ClinicalTrials.gov
Countries: China
- Tianjin, China – Institute of Hematology & Blood Diseases Hospital
Ages 18 to 70
Contact the trial teamTests ARD103 cell therapy in adults with relapsed or refractory leukemia or MDS
NCT06680752 · ClinicalTrials.gov
Countries: United States
- Charlotte, United States – Novant Health Cancer Institute
- Houston, United States – MD Anderson Cancer Center
- Winston-Salem, United States – Novant Health Cancer Institute
Age 18 and over
Contact the trial teamTests LILRA6 CAR-T cells in adults with relapsed or refractory acute myeloid leukemia
NCT07263906 · ClinicalTrials.gov
Countries: China
- Hangzhou, China – The Second Affiliated Hospital,School of Medicine,Zhejiang University
Ages 18 to 75
Contact the trial teamTesting CT0991 CAR-T Cells for Relapsed or Refractory Acute Myeloid Leukemia
NCT07233018 · ClinicalTrials.gov
Countries: China
- Wuhan, China – Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Ages 18 to 75
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial teamTests donor immune cells engineered to attack relapsed or resistant acute myeloid leukemia
NCT07026942 · ClinicalTrials.gov
Countries: United States
- Columbus, United States – Nationwide Children's Hospital
Ages 1 to 39
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial team
Showing 40 of 60. Use the filters to narrow the list.
How to get into an early trial
- A lab does not treat patients, so you cannot phone the lab to get a new treatment.
- Ask your doctor to look at phase 1 trials with you. These are the first tests in people.
- If one fits, your doctor sends a referral to the trial centre.
- The trial team checks whether you can join and decides.
Trial data: ClinicalTrials.gov, courtesy of the U.S. National Library of Medicine; it does not endorse this site. EU trials: EU Clinical Trials Information System (CTIS), European Medicines Agency. We show the registry records; the trial team has the last word on who can join.
Latest research
The five newest articles. The label comes from the PubMed index: whether it was tested in people, in animals or only in the lab.
- Higher Relapse Rate and Resource Utilization With Ara-C Consolidation Chemotherapy Alone Compared to Hematopoietic Cell Transplantation in First Remission in a Cohort of Younger Adults With Acute Myeloid Leukemia With t(8;21) (q22;q22.1).J Hematol · 2026-10-31
- In animalsAll-Trans Retinoic Acid-Loaded Fe-N3-Se Single-Atom Nanozymes Enable Redox-Guided Differentiation Therapy for Acute Myeloid Leukemia.ACS Nano · 2026-11-17
- In animalsIntravital Microscopy-Guided Live-Cell Isolation for Spatially Resolved Transcriptional Analysis of Leukemia-Immune Interactions.J Vis Exp · 2026-11-10
- Impact of Molecular and Cytogenetic Risk Stratification, Early Treatment Response, and Inflammatory Biomarkers on Survival in Intensively Treated Non-Acute Promyelocytic Leukemia Acute Myeloid Leukemia.World J Oncol · 2026-11-11
- In peopleEarly bone marrow-guided venetoclax management in frontline unfit acute myeloid leukemia: a two-stage real-world study.Ann Hematol · 2026-08-20
Is it true?
Saw something on social media? Fact-check it now.
Get screened
For family members and people at higher risk: free checks can find some cancers early, before there are symptoms.
There is no routine screening for this cancer. If you have symptoms or a family history, talk to your doctor.
If several people in your family had cancer, ask your GP whether genetic counselling makes sense for you.
Offer tissue or data
You can help research move faster.
Give tissue or blood to research
Before an operation or a blood test, ask if left-over tissue or blood can go to a biobank.
- Does this hospital have a biobank?
- What will the sample be used for, and for how long?
- Can I change my mind later?
Share your health data
Ask your doctor whether there is a patient registry for your illness. You choose what you share.
Take part as a healthy volunteer
Some studies need people without the illness, often family members.
Volunteer studiesGet support
Patient groups in Austria
- Österreichische Krebshilfe
Free, anonymous counselling at regional centres in every federal state, psycho-oncology and emergency financial aid.
Phone: 01 7966450
Help for every illness in Austria (4)
- 1450 – Rund-um-die-Uhr-Gesundheitsberatung
Austria's nationwide 24/7 telephone health advice line: trained staff assess symptoms and guide callers to the appropriate care.
- Telefonseelsorge Österreich – Notruf 142
Free, confidential 24/7 emotional support and crisis line for anyone in Austria, reachable on 142.
- Gesundheitsportal Österreich (gesundheit.gv.at)
Austria's official public health portal, offering quality-assured information on diseases, prevention, health services and patient rights.
- ARGE Selbsthilfe Österreich
ARGE Selbsthilfe Österreich represents the interests of self-help groups and patient organisations in Austrian social and health policy.
Available abroad: international groups (8)
- DKMS
Finds blood stem cell donors worldwide so that people with blood cancer can have a transplant.
- Acute Leukemia Advocates Network (ALAN)
Global network of 69 acute leukaemia patient organisations (hosted by the Swiss Leukemia Patient Advocates Foundation); member list helps patients find a national group.
- European Cancer Patient Coalition (ECPC)
Umbrella of European cancer patient groups, with a patient toolbox and a legal network for cancer patients.
- European Reference Networks (European Commission)
The European Commission's 24 expert networks for rare and complex diseases; your doctor can contact them.
- EURORDIS – Rare Diseases Europe
Alliance of over 1,000 rare disease patient organisations, with a list of rare disease helplines by country.
- Workgroup of European Cancer Patient Advocacy Networks
Network of pan-European cancer patient umbrella groups (including the blood cancer networks): joint advocacy, WECAN Academy training for patient advocates, patient experience data courses.
- European Patients' Forum (EPF)
Umbrella of European patient organisations and national patient coalitions.
- International Alliance of Patients' Organizations
Global alliance of patient organisations of all diseases, promoting patient-centred healthcare.
Money and work
If the illness stops you working, ask the hospital social worker which benefits you can claim.
- Which sick-pay or disability benefits can I apply for?
- Is there help for the carer in the family?
- Are travel costs to treatment paid back?
After a loss
If someone you love has died, you do not have to go through it alone. Many families ask themselves whether they missed something; the care team can talk this through with you.
We have no grief support group in Austria in our list yet. The hospital's social worker or palliative team can tell you where to find one.
Hospitals and hospices have chaplains and counsellors, for any faith or none.
Some families decide to give tissue to research after death, so that the illness can be studied. If you want to, ask the treating hospital early whether it has such a programme.
Access and cost
- If no trial fits, your doctor can ask the company and the medicines authority whether early access (compassionate use) is possible.
- In Austria the medicines agency BASG lists the early-access programmes that are running. BASG (Austria): list of compassionate use programmes, no. 054
- In the EU you may get planned care in another EU country. Ask your health insurer before you go. Your Europe: planned medical treatment abroad
- Some medicines for this disease are approved abroad but maybe not here: see “Approved elsewhere” under “Approved in Austria” above.
Don't pay for this
No one will cure you through a Facebook message or ask you to invest money.
- Animal worm medicines bought online (ivermectin, fenbendazole)
They are made for animals and not tested for cancer in people. High doses can cause seizures or coma, fenbendazole has caused liver damage, they may weaken your cancer treatment, and they can keep you out of a trial.
American Cancer Society: What to Know About Ivermectin (21 May 2026) · American Cancer Society: What to Know About Fenbendazole (21 Oct 2025) · ASCO: Oncologists urged to discuss ivermectin and fenbendazole (17 Jun 2026)
- “Treatment plans” offered in comments
Ask which published study in people is behind it. Usually there is none.
- Anyone who answers your post with a private treatment
Real trials are listed in a public registry. Check the number on ClinicalTrials.gov or the EU trial register.
- Strangers offering investments or “funds” for treatment
Do not reply and do not send money. Report the comment or message.
Before you pay for anything, ask three things
- Can I have a written price, with everything that is included?
- Which published study in people shows it helps my disease?
- What does my doctor say about it?
Questions for your doctor
Ready lists for a new diagnosis, during treatment, before a trial and before you pay. Open the question lists
Not medical advice. We show what is open and what is known; your care team decides what fits you.